Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 3/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 6/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA7 | P43166 | 2/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30450003 | 0.84 | ATM (0.36) | ALDH1A1MAPK1 | |
| SCHEMBL30450496 | 0.80 | KMT2A (0.37) | PPARAPPARGCTSSAAK1CA2 | |
| SCHEMBL25826817 | 0.79 | ADORA2A (0.41) | CA2CA1CA9ALDH1A1 | |
| SCHEMBL31465655 | 0.79 | NPSR1 (0.34) | AAK1ALDH1A1 | |
| SCHEMBL25826914 | 0.79 | NPSR1 (0.34) | AAK1ALDH1A1 | |
| SCHEMBL31304940 | 0.78 | PPARA (0.38) | PPARAPPARGCTSSCTSKALDH1A1 | |
| SCHEMBL29456690 | 0.75 | KDM4E (0.44) | CA2CA1CA9ALDH1A1MAPK1 | |
| SCHEMBL31304946 | 0.75 | ALDH1A1 (0.37) | ALDH1A1 | |
| SCHEMBL19403329 | 0.74 | KMT2A (0.40) | CTSSAAK1CA2CA1CA7 | |
| SCHEMBL19403330 | 0.74 | KMT2A (0.40) | CTSSAAK1CA2CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739694-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS INC (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025010294-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-4460498-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023133375-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074920-A1 | MACROCYCLIC COMPOUNDS AND USE AS KINASE INHIBITORS | MAP3K20, MAP3K8, PRKACA | PPARA 3451/4885PPARG 1727/4885CTSS 1353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.